Trials / Completed
CompletedNCT03073109
Patient-Reported Outcomes In Rheumatoid Arthritis Patients Treated With Tofacitinib Or Biological Disease-Modifying Antirheumatic Drugs (DMARDs) In Real Life Conditions
PATIENT-REPORTED OUTCOMES IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOFACITINIB OR BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS) IN REAL LIFE CONDITIONS
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 170 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is aimed to describe the outcomes related to physical activity, activity of disease, quality of life, work productivity and safety in Latin-American patients with Rheumatoid Arthritis (RA) treated with tofacitinib or biological DMARDs after failure to respond to conventional DMARDs in real-life conditions. This will be a non-interventional, hybrid study (prospective and retrospective data collection) comparing tofacitinib to biologic DMARD treatments in patients with RA after failure of conventional DMARDs. The population will be composed by adult patients over 18 years of age diagnosed with RA and who have been prescribed tofacitinib or any biological DMARDs.
Conditions
Timeline
- Start date
- 2017-03-15
- Primary completion
- 2019-09-16
- Completion
- 2019-09-16
- First posted
- 2017-03-08
- Last updated
- 2020-10-22
- Results posted
- 2020-10-22
Locations
13 sites across 2 countries: Colombia, Peru
Source: ClinicalTrials.gov record NCT03073109. Inclusion in this directory is not an endorsement.